SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
Globe Newswire•22/10/2026•08:00 ET
0
Key Highlights
- ➤SCY-247 IV Phase 1 generally well tolerated, with no drug-related serious adverse events
- ➤IV doses of 50 mg once daily or higher reached murine efficacy-target exposures
- ➤SCYNEXIS expects Phase 2 oral and IV development in 2027, subject to FDA agreement
- ➤BARDA contract provides up to approximately $214 million in non-dilutive SCY-247 funding
- ➤SCYNEXIS maintains SCY-770 Phase 2 plans for Q4 2026 and cash runway into 2029
Expert Statements
Todd Minga, M.D., SVP of Research and Development at Scynexis
“With Phase 1 studies of both the intravenous and oral formulations of SCY-247 now complete, we can refine our plans for the next stage of development of this second-generation fungerp, designed to address the growing threat of antimicrobial resistance”
Todd Minga, M.D., SVP of Research and Development at Scynexis
“Having both intravenous and oral formulations could provide flexibility in managing patients with invasive candidiasis and those at risk of invasive fungal diseases”
Todd Minga, M.D., SVP of Research and Development at Scynexis
“We look forward to initiating a Phase 2 study next year, subject to agreement with the FDA.”
* Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
* Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
Get started
Create a free account to read the full story.